1 Hetts SW, "To die or not to die:an overview of apoptosis and it's role in disease" 298 : 300-307, 1998
2 Adams JM, "The Bcl-2 protein family; Arbiters of cell survival" 281 : 1322-1325, 1998
3 Hsu CD, "Serum soluble Fas in preeclampsia" 97 : 530-532, 2001
4 Zhou Y, "Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts" 91 : 950-60, 1993
5 Allaire AD, "Placental apoptosis in preeclampsia" 96 : 271-276, 2000
6 Diket AL, "Nitric oxide inhibition causes intrauterine growth retardation and hind-limb disruptions in rats" 171 : 1243-8, 1994
7 Gerresten G, "Morpholoical changes of the spiral arteries in the placenta bed in relation to preeclampsia and fetal growth retardation" 88 : 876-81, 1981
8 Heyborne KD, "Interleukin-10 in amniotic fluid at midtrimester:Immune activation and suppression in relation to fetal growth" 171 : 55-61, 1994
9 Need JA, "Immunological phenomena in preeclamptic toxemia" 6 : 443-60, 1979
10 Dekker GA, "Immune maladaptation in the etiology of preeclampsia:A review of corroborative epidemiologic studies" 53 : 377-382, 1998
1 Hetts SW, "To die or not to die:an overview of apoptosis and it's role in disease" 298 : 300-307, 1998
2 Adams JM, "The Bcl-2 protein family; Arbiters of cell survival" 281 : 1322-1325, 1998
3 Hsu CD, "Serum soluble Fas in preeclampsia" 97 : 530-532, 2001
4 Zhou Y, "Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts" 91 : 950-60, 1993
5 Allaire AD, "Placental apoptosis in preeclampsia" 96 : 271-276, 2000
6 Diket AL, "Nitric oxide inhibition causes intrauterine growth retardation and hind-limb disruptions in rats" 171 : 1243-8, 1994
7 Gerresten G, "Morpholoical changes of the spiral arteries in the placenta bed in relation to preeclampsia and fetal growth retardation" 88 : 876-81, 1981
8 Heyborne KD, "Interleukin-10 in amniotic fluid at midtrimester:Immune activation and suppression in relation to fetal growth" 171 : 55-61, 1994
9 Need JA, "Immunological phenomena in preeclamptic toxemia" 6 : 443-60, 1979
10 Dekker GA, "Immune maladaptation in the etiology of preeclampsia:A review of corroborative epidemiologic studies" 53 : 377-382, 1998
11 Cunningham FG,, "Hypertensive disorders in pregnancy" McGraw Hill Co 567-618, 2001
12 Eskenazi B, "Fetal growth retardation in infants of multiparous and nulliparous women with preeclampsia" 1112-8, amjobstetgynecol1993
13 Griffith TS, "Fas ligand induced apoptosis as a mechanism of immune privilege" 270 : 1189-1192, 1995
14 Kuntz TB, "Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia" 50 : 743-749, 2001
15 Bamberger AM, "Expression of apoptosis inducing Fas ligand (FASL) in human first and third trimester placenta and choriocarcinoma cells" 82 : 3173-3175, 1997
16 Laskowska M,, "Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation" 2005;Sep
17 Roh CR, "Differential expression of Fas and Fas ligand in human placenta" 17 : 213-216, 2002
18 Kerr IFR, "Definition and incidence of apoptosis the molecular basis of programmed cell death" Cold Spring Harbor Laboratory Press 5-29, 1991
19 Gabriel R, "Alteration of epidermal growth factor receptor in placental membranes of smokers:relationship with intrauterine growth retardation" 170 : 1238-43, 1994
20 Robert JM, "A new development in preeclampsia" Edward Arnold Publishers 125-42, 1990